Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Radotinib |
BCR-ABL Tyrosine Kinase Inhibitor | Hematologic (Leukemia) | ||
|
Molecule
Radotinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
BCR-ABL Tyrosine Kinase Inhibitor |
||||
Ramucirumab |
Anti-VEGF / VEGFR Agent | Solid Tumour | ||
|
Molecule
Ramucirumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
||||
Rebastinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Rebastinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Refametinib |
BRAF / MEK Inhibitor | Solid Tumour | ||
|
Molecule
Refametinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
||||
Regorafenib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Regorafenib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Relacorilant |
Selective Glucocorticoid Receptor Antagonist (first-in-class) | Solid Tumour | ||
|
Molecule
Relacorilant
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Selective Glucocorticoid Receptor Antagonist (first-in-class) |
||||
Remestemcel-L |
Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Therapy | Hematologic | ||
|
Molecule
Remestemcel-L
Therapeutic Category
Cellular Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Therapy |
||||
Repotrectinib |
ALK / ROS1 / NTRK Inhibitor | Solid Tumour | ||
|
Molecule
Repotrectinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
||||
Resminostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Resminostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Retifanlimab |
Anti-PD-1 mAb | Both (Solid & Hematologic) | ||
|
Molecule
Retifanlimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
||||
Revumenib |
EZH2 / Menin Inhibitor | Hematologic | ||
|
Molecule
Revumenib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
||||
Rezivertinib |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Rezivertinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
RadotinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
BCR-ABL Tyrosine Kinase Inhibitor |
|
RamucirumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
|
RebastinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
RefametinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
|
RegorafenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
RelacorilantTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Selective Glucocorticoid Receptor Antagonist (first-in-class) |
|
Remestemcel-LCellular Therapy |
|
|
Therapeutic Category
Cellular Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Therapy |
|
RepotrectinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
|
ResminostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
RetifanlimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
|
RevumenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
|
RezivertinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|